Amid opioid crisis, insurers restrict pricey, less addictive painkillers

A UnitedHealthcare facility in Cypress, Calif. The company stopped covering the less risky pain drug Butrans. /CreditMike Blake/Reuters

Drug companies and doctors have been accused of fueling the opioid crisis, but some question whether insurers have played a role, too

By Katie Thomas and Charles Ornstein | The New York Times

At a time when the United States is in the grip of an opioid epidemic, many insurers are limiting access to pain medications that carry a lower risk of addiction or dependence, even as they provide comparatively easy access to generic opioid medications.

The reason, experts say: Opioid drugs are generally cheap while safer alternatives are often more expensive.

Drugmakers, pharmaceutical distributors, pharmacies and doctors have come under intense scrutiny in recent years, but the role that insurers — and the pharmacy benefit managers that run their drug plans — have played in the opioid crisis has received less attention. That may be changing, however. The New York State attorney general’s office sent letters last week to the three largest pharmacy benefit managers — CVS Caremark, Express Scripts and OptumRx — asking how they were addressing the crisis.

READ ON:

Share this!

Additional Articles

News Categories

Get Our Twice Weekly Newsletter!

* indicates required

Rose Law Group pc values “outrageous client service.” We pride ourselves on hyper-responsiveness to our clients’ needs and an extraordinary record of success in achieving our clients’ goals. We know we get results and our list of outstanding clients speaks to the quality of our work.

September 2017
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930